Skip to main content

Table 3 Best response among patients with overall and measurable disease (FAS)

From: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

Disease

Overall response rate

n (%)

Complete response

n (%)

Partial response

n (%)

Stable disease

n (%)

Progressive disease

n (%)

Total

n (%)

Overalla (n = 127)

 n (%)

31 (24.4)

4 (3.1)

27 (21.3)

56 (44.1)

40 (31.5)

127 (100.0)

 95% CI

17.2–32.8

0.9–7.9

14.5–29.4

35.3–53.2

23.5–40.3

97.1–100.0

Measurableb (n = 113)

 n (%)

29 (25.7)

3 (2.7)

26 (23.0)

47 (41.6)

37 (32.7)

113 (100.0)

 95% CI

17.9–34.7

0.6–7.6

15.6–31.9

32.4–51.2

24.2–42.2

96.8–100.0

  1. FAS full analysis set, CI confidence interval, Overall response rate = CR + PR
  2. aPatients with or without measurable disease at baseline and response data available as per RECIST v1.1
  3. bPatients with measurable disease at baseline as per RECIST v1.1 and response data available as per RECIST v1.1